The longitudinal pattern of lung function in children with sickle cell anemia (SCA) has shown a decrease in FEV 1 % predicted, a risk factor for death in adults with SCA, but predictors for this decline are poorly characterized. In a prospective longitudinal multi-center cohort of children with SCA, we tested the hypotheses that: (1) FEV 1 % predicted declines over time; and (2) SCA-specific characteristics and therapy predict this decline. At three clinical centers, children with SCA (HbSS or HbSb 0 thalassemia), unselected for respiratory disease, were enrolled in the Sleep and Asthma Cohort (SAC) study. Study-certified pulmonary function technicians performed spirometry and lung volumes. Each assessment was reviewed centrally. Predicted values were determined for TLC, FEV 1 , FVC, and FEV 1 /FVC ratio. A total of 197 participants, mean age 11.0 years at first testing (range 4-19.3 years), had a minimum of three spirometry measurements, over an average of 4.4 years (range 1.1-6.5 years) from baseline to endpoint. In a multivariable model, FEV 1 % predicted declines by 0.3% for every additional year of age (95% CI 20.56 to 20.05, P 5 .020). Sex, asthma history, hemoglobin, reticulocyte count, white blood cell count, incidence rate of severe acute pain and acute chest syndrome episodes, and hydroxyurea therapy were not associated with a decline in FEV 1 % predicted. In a large, rigorously evaluated, prospective cohort of an unselected group of children with SCA, FEV 1 % predicted declines minimally over an average of 4 years, and none of the examined disease features predict the decline.
| I N TR ODU C TI ON
Pulmonary abnormalities are being increasingly recognized as a significant cause of morbidity and mortality in sickle cell anemia (SCA), including acute chest syndrome (ACS), asthma, recurrent wheezing, sleep-disordered breathing, dyspnea, and pulmonary hypertension.
Improved childhood survival has resulted in increased recognition of chronic lung disease in older patients with SCA. Studies are now beginning to explore the impact of pulmonary complications on lung function for adults and children with SCA. 1 While most children with SCA have lung function within normal limits, 2,3 lung growth is significantly reduced compared to age and race-matched controls 4 and adulthood lung restrictive defects are commonly reported. 5, 6 However, few studies have prospectively evaluated the longitudinal trajectory of lung function in children with SCA.
Decreased FEV 1 % predicted has been associated with an increased risk for earlier death in the general population [7] [8] [9] and in individuals with cystic fibrosis. 10, 11 Similarly, longitudinal data from the Cooperative Study of Sickle Cell Disease (CSSCD) showed that adults with SCA who had a decrease in expiratory volume in 1 second (FEV 1 ) died earlier, over the course of five years, compared to those who did not. 12 This article has an online data supplement, which is accessible from this issue's table of content online.
Only three studies have been performed in children with SCA to understand what factors, if any, contribute to a longitudinal decline in FEV 1 % predicted. The three prior studies, two retrospective and one prospective, have shown variability in the magnitude of FEV 1 % predicted decline over time (0.9-3.3% per year) [13] [14] [15] leading to difficulty for providers in interpreting this change.
None of the previous studies have accounted for intraindividual variability of the test results using the coefficient of variation (CV), which gives an estimation of the expected participant biological and instrument variability. 16 We tested the hypothesis that children with SCA have a decline in FEV 1 % predicted and SCA-specific characteristics, treatment with hydroxyurea, or both, predict a decline in FEV 1 % predicted. We also sought to interpret any observable change in lung function relative to a calculated age-based CV for children with SCA.
| M E TH ODS

| Study design and recruitment
The Sleep and Asthma Cohort (SAC) is a prospective cohort study of children and adolescents with SCA, unselected for respiratory disease. Participants ranged from 4 to 18 years of age and were enrolled and were known to be human immunedeficiency virus (HIV) positive. After the start of the study, data from participants initiated on chronic blood transfusion therapy were censored from this point forward due to the known decrease in pain events following initiation of chronic transfusion therapy. Parents provided written informed consent for all participants and patients provided assent when appropriate. Full manual of operations for the study design can be provided upon request.
| Pulmonary function testing
Pulmonary function tests were obtained when participants were at least 4 weeks after discharge from the hospital for SCA complications and at baseline health without current illness, pain, or acute respiratory symptoms. Pulmonary function testing (spirometry and body plethysmography) was done at study enrollment and then at least annually during the study period. Total number of pulmonary function tests was highly dependent on participants' ability to perform the test with adequate quality control measures. Spirometry was performed using best maximal effort as selected by study certified pulmonary function technicians using a pneumotachograph-type spirometer interfaced with a personal computer system (Jaeger MasterScope; VIASYS, Hoechberg, 
| Clinical covariates
Postulated covariates were selected due to their proposed impact on lung disease in children with SCA and included: age at enrollment, sex, baseline hemoglobin level, baseline white blood cell count, baseline reticulocyte count, incidence rates of acute pain or ACS episodes, treatment with hydroxyurea at baseline and throughout the study, and a history of asthma. 28 Asthma was defined as a clinical diagnosis made by a physician coupled with current use of asthma medication. 29 ACS was defined as a new clinical or radiographic pulmonary density in the context of an acute illness characterized by respiratory symptoms (cough, wheezing, rales, chest pain, decreased oxygen saturation (>2%) from baseline, use of accessory muscles of respiration, or increased respiratory rate) with or without fever. Pneumonia was included in this
definition. An acute pain episode was defined as a hospitalization for SCA-associated pain, excluding headaches, and requiring opioid treatment. All ACS and pain episodes in the first three years of the study were reviewed by a single investigator at each participating site with over-reading by the principal investigator (M.R.D), to ensure uniform definitions of ACS and pain in this multi-center study.
| Coefficient of variation
A separate sub-analysis to calculate the CV was performed. Participants with 2 spirometry measurements within a 6-month window were included in the sub-analysis. The CV was calculated from these paired spirometry measurements for FEV 1 % predicted, FVC% predicted, and FEV 1 /FVC% predicted. For the group of paired measurements, the CV is the ratio of the standard deviation (SD) of the mean to the mean value of all measurements. The CV was calculated separately for paired measurements in participants below and above 16 years of age. We selected to have two separate CV for older and younger participants to allow for anticipated improvement in reproducible spirometry technique when comparing the effort of a 4 year old compared to a 16 year old.
| Comparison to adult cohort of participants with SCA
To predict if children in our cohort would have a rate of decline in 
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. 30 We also analyzed a more contemporary cohort of adults with 
| R E SU LTS
| Demographics
A total of 223 participants were enrolled and had spirometry measurements performed. Of these participants, 197 were eligible for the primary analysis as they had at least three (range 3-8) spirometry measurements performed over a minimum follow up of 1 year (range 1.1-6.5 years). The only statistical differences in demographic features were in age, as the excluded group were younger (median 8.8 years versus 10.7 years). The only differences in 16 baseline clinical or laboratory features were the excluded group had a higher proportion of bronchodilator response to albuterol and a slightly lower baseline FEV 1 % predicted (mean 82.8 versus 88.5), Supporting Information Table S1 . Mean age of our final cohort at first testing was 11.0 years (range 4-19.3 years). Table 1 shows descriptive statistics of the final sample. Supporting Information Figure S1 provides a schematic of our study design.
3.2 | Age is the only covariate predictive of a significant decline in FEV 1 % predicted 
| D ISC USSION
In a large prospective, rigorously evaluated study of 197 children with SCA who had undergone a minimum of three spirometry measurements over a median of 4.7 years, we have demonstrated that children have a very small decline in FEV 1 % predicted over time (0.3% per year) and none of the expected covariates were associated with this decline.
This observed change was considerably less than the predicted average yearly decline that has been previously reported. 14, 15, 33 Table S4 .
The distribution of lung function categorization found in our cohort at baseline is similar to reports in other cohorts of children with SCA. 15, 33 While a change in lung function pattern was observed in some of our study population, this pattern was not significant or predictable over time. Our data suggest that significant progression from normal to restrictive defects may not begin in childhood.
A critical component in interpreting longitudinal changes in FEV 1 % predicted in the current study and all previous studies, is the coefficient of variation. Unfortunately none of the prior three studies estimating based on the available literature at the time of study entry. Additionally, while we followed a large number of participants, the mean duration was approximately 4 years and the mean age was 11 years. Quite possibly our participants were too young and followed for too short of a period of time to demonstrate a large change in lung function during the study period.
Based on the substantial discrepancy between observed and expected FEV 1 % predicted in adults with SCA, we postulate that there is a greater change in lung function occurring beyond the average age in our cohorts, 11.0 years, and below the age of the CSSCD and Vanderbilt-Meharry
Sickle Center adult cohorts, 32 years. We postulate our cohort simply did not have a sufficient long enough follow-up period to identify possible clinical risk factors that may result in significant decline in FEV 1 % predicted observed in adults with SCA. Furthermore, as has been suggested in children with cystic fibrosis, 38 conventional spirometry may not be the best tool to test for lung disease in children with SCA. Consideration should be given to predictors of lung disease such as lung clearance index and assessment of lung structure to truly capture early lung disease in children.
In a large, rigorously evaluated, and prospective research cohort of children with SCA, FEV 1 % predicted declined minimally over an average of 4 years, and none of the SCA specific clinical characteristics significantly predicted a decline in lung function. Additionally, we found that the small FEV 1 % predicted decline in children was discrepant with the observed average FEV 1 % predicted in two adult cohorts. New longitudinal studies that extend across the transition age group into adulthood and more refined pulmonary function assessment methods are needed to further explore the impact of sickle cell lung disease on pulmonary growth and function in young adults with SCA.
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